<DOC>
	<DOCNO>NCT00125606</DOCNO>
	<brief_summary>For patient acute myeloid leukemia ( AML ) , allogeneic hematopoetic stem cell transplantation ( HSCT ) one potent treatment option currently available . In order overcome high risk fatal treatment-related complication , reduce intensity nonmyeloablative conditioning regimen allogeneic HSCT currently explore various hematological malignancy include AML . At least allogeneic HSCT AML , optimal dose-intensity preparative regimens disease control acceptable rate treatment-related lethal complication determine . The investigator , therefore , evaluate reduced intensity myeloablative conditioning 8 Gy TBI fludarabine AML patient consider ineligible conventional conditioning phase 2 trial ( data publish BLOOD Stelljes et al. , 2005 ) . The result suggest 8 Gy TBI/fludarabine , condition relate unrelated donor transplant perform AML patient first second complete remission ( CR ) remarkably low 2-year non relapse mortality ( NRM ) satisfactory disease control . Based data randomize phase 3 trial patient AML CRâ‰¥2 currently conduct Cooperative German Transplant Study Group compare TBI 8 Gy/fludarabine conventionally dose condition TBI 12 Gy/cyclophosphamide .</brief_summary>
	<brief_title>Phase 3 Trial AML Patients CR2 Comparing 8Gy TBI /Fludarabine Conditioning With TBI 12Gy/Cyclophosphamide</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients AML second complete remission HLAidentical relate ( HLA * A , B , DR ) HLAcompatible unrelated donor maximum one Ag mismatch Ages 1860 year Written inform consent patient Written inform consent donor No major organ dysfunction Cardiac failure ( New York Heart Association [ NYHA ] grade IIIV ) Renal failure ( creatinine &gt; 2.0 mg/dl ) Hepatic failure ( total bilirubin &gt; 3 mg/dl ) Severe neurological/psychiatric disorder Previous allogeneic HSCT Contraindications use drug HIV infection Noncompliance processing personal data accord protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>AML</keyword>
	<keyword>allogeneic HSCT</keyword>
	<keyword>reduce intensity conditioning</keyword>
	<keyword>randomize trail</keyword>
</DOC>